Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Rash, liver dysfunction, and diarrhea are known major adverse events associated with erlotinib and gefitinib. However, clinical trials with gefitinib have reported different proportions of adverse events compared to trials with erlot...

Full description

Bibliographic Details
Main Authors: Suzumura Tomohiro, Kimura Tatsuo, Kudoh Shinzoh, Umekawa Kanako, Nagata Misato, Matsuura Kuniomi, Tanaka Hidenori, Mitsuoka Shigeki, Yoshimura Naruo, Kira Yukimi, Nakai Toshiyuki, Hirata Kazuto
Format: Article
Language:English
Published: BMC 2012-12-01
Series:BMC Cancer
Subjects:
CYP2D6
Non-small cell lung cancer
Gefitinib
Erlotinib
Adverse events
Online Access:http://www.biomedcentral.com/1471-2407/12/568

Internet

http://www.biomedcentral.com/1471-2407/12/568

Similar Items